XML 28 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
License and Collaboration Agreements - Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total $ 36,558,000 $ 27,815,000 $ 51,399,000 $ 40,849,000  
Baxalta [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total   0   0  
Sanofi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total     0    
License and Collaboration Agreements [Member] | Baxalta [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Proportional Performance Model 16,558,000   31,399,000    
Substantive Milestones 20,000,000   20,000,000    
Total 36,558,000   51,399,000    
Accounts receivable, billed 807,000   807,000    
Accounts receivable, unbilled 907,000   907,000   $ 1,615,000
Deferred revenue $ 64,611,000   $ 64,611,000   91,156,000
License and Collaboration Agreements [Member] | Sanofi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront payment   13,268,000   14,518,000  
Milestone payments   5,529,000   6,049,000  
Development services   3,040,000   13,740,000  
Manufacturing services and other   5,978,000   6,542,000  
Total   $ 27,815,000   $ 40,849,000  
Accounts receivable, billed         369,000
Accounts receivable, unbilled         $ 1,282,000